"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
| Descriptor ID |
D019386
|
| MeSH Number(s) |
D02.705.429.500.100
|
| Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 1 | 4 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Jacobson DL, Lindsey JC, Gordon C, Hazra R, Spiegel H, Ferreira F, Amaral FR, Pagano-Therrien J, Gaur A, George K, Benson J, Siberry GK. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clin Infect Dis. 2020 08 22; 71(5):1281-1288.
-
Ayyoub S, Coyne C. VISUAL VIGNETTE. Endocr Pract. 2018 Nov; 24(11):1020.
-
Lin D, Kramer JR, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, Parente P, Graham DY, El-Serag HB. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
-
Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013 Mar 23; 13:15.
-
Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009 Feb; 24(2):196-208.
-
Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009 Apr; 44(4):639-47.
-
Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr; 40(4):843-51.
-
Meadows ES, Stock J, Johnston JA. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making. 2006 Nov-Dec; 26(6):633-5; author reply 636-7.
-
Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006 Oct; 15(10):710-8.
-
Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int. 2006; 17(8):1268-74.